Hypoxia and Medicine - Hypoxia News

Hypoxia News

2011 Gulf of Mexico 'dead zone' could be biggest ever Monday, July 18, 2011 @ 2:21PMResearchers have examined the scope and size of this year's "dead zone" in the Gulf of Mexico and have measured it currently to be about 3,300 square miles, or roughly the size of Delaware and Rhode Island combined, but some researchers anticipate it becoming much larger.
Gulf 'dead zone' may triple in size Monday, July 18, 2011 @ 2:17PMResearchers measuring the "dead zone" in the Gulf of Mexico say it is currently about 3,300 square miles but some scientists say it could become much larger.
Texas A&M research team says Gulf dead zone may expand Sunday, July 17, 2011 @ 12:38AMA team of Texas A&M oceanography researchers recently spent five days at sea taking measurements of this year's dead zone in the Gulf of Mexico, which they determined to be about the size of Rhode Island and Delaware combined. But scientists ...
This Week in Cancer Research Saturday, July 16, 2011 @ 12:14AMIn Cancer Research this week, researchers from the US and China say that the in vivo programming of tumor antigen-specific T lymphocytes from pluripotent stem cells promotes cancer immunosurveillance . In this study, the team shows that highly reactive antigen-specific cytotoxic T-cells can be generated from induced pluripotent stem cells to provide an unlimited source of functional cytotoxic T ...
Gulf dead zone already bigger than Delaware Friday, July 15, 2011 @ 5:23AMshare: digg facebook twitter DiMarco's was the first comprehensive cruise of the northern Gulf of Mexico to be conducted in June. Since the mid-1980s, a Louisiana-based group led by Nancy Rabalais has cruised the Gulf nearly every July, the end of which being when dead zones are believed to peak. Finding a dead zone off the Texas coast this summer was mildly surprising, as the state's drought ...
Scientists measure gulf 'dead zone' Thursday, July 14, 2011 @ 7:08PMCOLLEGE STATION, Texas, July 14 (UPI) -- Researchers measuring the "dead zone" in the Gulf of Mexico say it is currently about 3,300 square miles but some scientists say it could become much larger.
2011 'Dead Zone' Could Be Biggest Ever Thursday, July 14, 2011 @ 2:59PMResearchers from Texas A&M University have returned from a trip to examine the scope and size of this year's "dead zone" in the Gulf of Mexico and have measured it currently to be about 3,300 square miles, or roughly the size of Delaware and Rhode Island combined, but some researchers anticipate it becoming much larger.
Sluggish movement at altitude is partly a brain effect Thursday, July 14, 2011 @ 11:55AMThe brain limits our ability to move at altitude, possibly to prevent damaging overexertion
Immune system suppression linked to blood vessel formation in tumors Wednesday, July 13, 2011 @ 2:21PMTargeted therapies that are designed to suppress the formation of new blood vessels in tumors, such as Avastin, have slowed cancer growth in some patients. However, they have not produced the dramatic responses researchers initially thought they might. Now, new research might help to explain the modest responses. The discovery suggests novel treatment combinations that could boost the power of ...
Penn study shows link between immune system suppression and blood vessel formation in tumors Wednesday, July 13, 2011 @ 12:30PM( University of Pennsylvania School of Medicine ) Targeted therapies that are designed to suppress the formation of new blood vessels in tumors, such as Avastin, have slowed cancer growth in some patients. However, they have not produced the dramatic responses researchers initially thought they might. Now, research from Penn might help to explain the modest responses. The discovery suggests ...
Penn Medicine News: Penn Study Shows Link Between Immune System Suppression and Blood Vessel Formation in Tumors Wednesday, July 13, 2011 @ 12:25PMPHILADELPHIA — Targeted therapies that are designed to suppress the formation of new blood vessels in tumors, such as Avastin (bevacizumab), have slowed cancer growth in some patients. However, they have not produced the dramatic responses researchers initially thought they might.
Scientists find link between immune system suppression, blood vessel formation in tumors Wednesday, July 13, 2011 @ 12:04PMTargeted therapies that are designed to suppress the formation of new blood vessels in tumors, such as Avastin (bevacizumab), have slowed cancer growth in some patients. However, they have not produced the dramatic responses researchers initially thought they might. Now, research from the Perelman School of Medicine at the University of Pennsylvania might help to explain the modest responses ...
Is the F-22 Too Difficult to Use? Wednesday, July 13, 2011 @ 4:11AMMany pixels have been spilled on the recent grounding of the F-22 Raptor fleet, problems with the plane's oxygen systems, and the possible role of the oxygen system in the November 2010 crash of an...
This Could be the Perfect Biotech Portfolio Tuesday, July 12, 2011 @ 11:48PMWhen it comes to biotech stocks, some investors like to swing for the fences. When that plan works, it feels great. Shareholders of Dendreon (Nasdaq: DNDN ) , for example, saw their
Q&A: U of Liverpool's Andrew Cossins Discusses Using Arrays, RNA-Seq to Study Exotic Species Tuesday, July 12, 2011 @ 5:59PMA zoologist by training , Andrew Cossins adopted microarray technology early to study environmental stress in non-model organisms.
Georgina Miranda: Everest: Summit, at What Cost? Tuesday, July 12, 2011 @ 1:15PMAfter three hours of restless sleep, I rose at 3 am to pack up my gear, test my oxygen mask, and start the ascent to the South Col (26,000 ft.), the fourth and final camp before the summit of Everest.
Cerulean launches Phase 2 study on lung cancer treatment Tuesday, July 12, 2011 @ 12:52PMCerulean Pharma Inc., a Cambridge company developing tumor-targeted nanopharmaceuticals, today said it has dosed the first patients in a Phase 2 clinical trial of its main drug candidate CRLX101, a potential therapy for non-small cell lung cancer.
Cerulean Pharma Doses First Patients in Randomized Phase 2 Clinical Study of CRLX101 in Non-Small Cell Lung Cancer Tuesday, July 12, 2011 @ 7:17AMCAMBRIDGE, Mass.--(BUSINESS WIRE)--Cerulean Pharma Inc. today announced the dosing of the first patients with CRLX101 in a randomized, controlled non-small cell lung cancer (NSCLC) Phase 2 clinical trial.
Researchers discover how genetic mutations cause rare human diseases Monday, July 11, 2011 @ 1:18AMResearchers at the University of California, San Francisco and in Michigan, North Carolina and Spain have discovered how genetic mutations cause a number of rare human diseases, which include Meckel syndrome, Joubert syndrome and several other disorders.
Campus Notes Monday, July 11, 2011 @ 1:16AMFLORIDA STATE UNIVERSITY
How Environmentalists Can Respond to Americans' Need for Personal Space Sunday, July 10, 2011 @ 8:20AMWhile reading about social science and environmental communication, I’ve noticed a gap between how environmentalists in the United States view personal space and how their audiences perceive it. If environmentalists tell audiences not to " say ‘eww’ to thrift stores ," avoid public transit , or live in suburbs , they may encounter resistance--not because their audiences are opposed to ...
Oxygen and temperature fluctuations alter goldfish gills [Life Lines] Friday, July 8, 2011 @ 11:19AMImage Source: The Goldfish Bowl: Canterbury Writers Gills are to fish what lungs are to mammals. This is where gas exchange between the animal and the environment takes place. As water flows across the gills, oxygen is taken up into the blood of the fish and carbon dioxide is removed. In both systems, oxygen is transported throughout the body by binding to hemoglobin molecules within red blood ...
3rd defendant guilty in murder case Thursday, July 7, 2011 @ 6:31PMHAMILTON - Riccardo Renfro, the third Middletown resident charged in the robbery and choking death of a man last summer has been found guilty.A Butler County jury returned the verdict just after 1:30 p.m. Thursday, after three hours of deliberation convicting the 20-year-old of murder and aggravated robbery for the death of Randy Manies.
3rd defendant Renfro found guilty in murder case Thursday, July 7, 2011 @ 1:31PMHAMILTON — Riccardo Renfro, the third Middletown resident charged in the robbery and choking death of a man last summer has been found guilty.A Butler County jury returned the verdict just after 1:30 p.m. Thursday, convicting the 20-year-old of murder and aggravated robbery for the death of Randy Manies.
3rd defendant found guilty in murder case Thursday, July 7, 2011 @ 1:02PMHAMILTON — Riccardo Renfro, the third Middletown resident charged in the robbery and choking death of a man last summer has been found guilty.A Butler County jury returned the verdict just after 1:30 p.m. today, convicting the 20-year-old of murder and aggravated robbery for the death of Randy Manies.
Software program could protect Florida's lakes, rivers from pollutants Thursday, July 7, 2011 @ 8:12AMAs a young scholar, Fernando Rios loved science and computer programming equally. So when Rios - who holds a bachelor's degree in physics from Canada's University of Waterloo - went looking for a graduate program, he discovered the Department of Scientific Computing at Florida State University, which has about 35 graduate students and launched a new undergraduate program of computational ...
New Software Aids Fight Against Nitrates In Florida's Groundwater Wednesday, July 6, 2011 @ 2:44PMAs a young scholar, Fernando Rios loved science and computer programming equally. So when Rios went looking for a graduate program, he discovered the Department of Scientific Computing at Florida State University. Now Rios has written an important and practical software program that could protect Florida's lakes and rivers from excessive pollutants.
Dendreon Announces Increased Capacity and Significant Reimbursement Decisions Supporting Broad Availability of PROVENGE Wednesday, July 6, 2011 @ 7:30AMDendreon Corporation announced significant milestones that support broad availability for on-label use of PROVENGEÂ® , the first autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer . Â
'Dead zones' prevalent off Myrtle Beach area coast Monday, July 4, 2011 @ 9:51PMSally Robinson sees it getting worse. More of the coral has lost color every time she dives the Freddy Day shipwreck.
Arkansas firm has stun method for killing chickens Monday, July 4, 2011 @ 3:06PMFORT SMITH, Ark. (AP) — Birds waiting to be slaughtered at the O.K. Industries plant on Sixth Street are "irreversibly stunned" before entering the processor's automated line, where workers turn them into breaded, seasoned and marinated chicken products.
Medical malpractice in Bangladesh Monday, July 4, 2011 @ 9:25AMDue to lack of monitoring by the government in the activities of private and public hospitals, medical malpractice and negligence in Bangladesh is rampant. While there are absolutely no data on the number of malpractice incidents that occur per week, most malpractice occur in the reputed hospitals and the most popular public ones. I faced
Ocean experts fear mass extinctions: As public debates man's role, study adds fuel to fire Sunday, July 3, 2011 @ 11:14PMSally Robinson sees it getting worse. More of the coral has lost color every time she dives the Freddy Day shipwreck.
Neuroprotective effect of Ceylon green tea Saturday, July 2, 2011 @ 2:48PMDr. Ranil de Silva, Faculty of Medical Sciences, University of Sri Jayewardenepura, will present the original research findings titled: "Protective effect of the Ceylon green tea in apoptosis of hypoxic human brain epithelial cells" at the 8th World Congress and 50th anniversary of the International Brain Research Organization (IBRO) which will be held in Florence (Italy)from July 14 to 18.
The dying oceans Saturday, July 2, 2011 @ 1:47PMOceans are at dire risk, a consortium of scientists, the International Program on the State of the Ocean (IPSO), warned in early June. The interdisciplinary group of specialists gathered at the University of Oxford in April examined the synergistic effects of diverse factors on the oceans for the first time. The group found that oceans are speeding toward biological collapse faster than ...
Phoenix girl survives near drowning Saturday, July 2, 2011 @ 2:17AMA 13-year-old girl who nearly drowned at a birthday party Friday has recovered from very critical condition, officials said.
Oxygen Orchard, Inc. Eyes Explosive Growth Friday, July 1, 2011 @ 8:13AMThe Company believes the Alternative Oxygen Therapy industry is poised for explosive growth. Â Oxygen Orchard, Inc. has been instrumental in shaping this new industry with its innovative products, informed by years of medical and scientific research.
Press Release Friday, July 1, 2011 @ 2:01AMBoston Therapeutics Inc. Posted on:01 Jul 11 Boston Therapeutics, Inc. , a public company registered with the SEC and a developer of diabetic therapies, today announced that it has granted Advance Pharmaceutical Company exclusive rights to market and sell SUGARDOWN™ in China.
P.M. Bay Area Buzz: East Bay house fire claims 97-year-old woman; Coroner determines Marin General Hospital staff left ... Thursday, June 30, 2011 @ 8:49PMOther top stories include: San Mateo officials OK permits for Peninsula pumpkin farm; Proposed sales tax might be put before Vallejo voters
Dendreon Announces Increased Capacity and Significant Reimbursement Decisions Supporting Broad Availability of PROVENGE Thursday, June 30, 2011 @ 6:54PMSEATTLE, June 30, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced significant milestones that support broad availability for on-label use of PROVENGE® (sipuleucel-T), the first autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer (mCRPC). The U.S. Food and Drug ...
Boston Therapeutics Licenses to Advance Pharmaceutical Exclusive Rights to Commercialize SUGARDOWN™ for Blood Sugar ... Thursday, June 30, 2011 @ 3:16PMMANCHESTER, N.H.--(BUSINESS WIRE)--Boston Therapeutics, Inc., a public company registered with the SEC and a developer of diabetic therapies, today announced that it has granted Advance Pharmaceutical Company exclusive rights to market and sell SUGARDOWN™ in China. Preliminary studies with SUGARDOWN™ demonstrate a significant reduction in post-meal excursion of blood glucose in humans ...
Threshold Pharmaceuticals Initiates Clinical Trial Evaluating TH-302 In Combination With Sunitinib Thursday, June 30, 2011 @ 2:31AMThreshold Pharmaceuticals, Inc., today announced the initiation of a Phase 1/2 dose escalation clinical trial of TH-302 in combination with sunitinib in patients with advanced renal cell carcinoma (RCC), gastrointestinal stromal tumor (GIST) and pancreatic neuroendocrine tumor (PNET).
FDA Approves Dendreon's Los Angeles Cancer Immunotherapy Manufacturing Facility Wednesday, June 29, 2011 @ 7:04PMDendreon Corporation today announced that the U.S. Food and Drug Administration approved its Los Angeles cancer immunotherapy manufacturing facility, allowing the company to continue to increase the availability of PROVENGEÂ® across the U.S. to help meet the needs of patients with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer. Â
Largest dead zone ever expected in Gulf Wednesday, June 29, 2011 @ 5:23PMScientists from Louisiana University Marine Consortium, LUMCON, are predicting that the “Dead Zone” — an area with low or no oxygen — in the Gulf of Mexico this year will be the largest ever. In scientific terms, this is called a “hypoxic” area.
Spl ambulances for newborns Wednesday, June 29, 2011 @ 4:04PMEvery time the paramedical staff on ambulances ferry newborn babies, they would tell their superiors that they need better facilities - warmers, incubators and tiny oxygen masks. Starting Wednesday, '108' staff will use two new ambulances, specially designed for babies less than a month old.
TGen Drug Development (TD2) Partnership With Imaging Endpoints Provides Comprehensive Clinical Trial Services For Drug ... Wednesday, June 29, 2011 @ 9:25AMTGen Drug Development (TD2) and Imaging Endpoints have teamed up to enable the rapid development of anti-cancer drugs and deliver them faster to patients in need, the companies announced recently.
Threshold commences combination Phase 1/2 trial of TH-302 and sunitinib for RCC, GIST and PNET Wednesday, June 29, 2011 @ 8:21AMThreshold Pharmaceuticals, Inc., today announced the initiation of a Phase 1/2 dose escalation clinical trial of TH-302 in combination with sunitinib in patients with advanced renal cell carcinoma (RCC), gastrointestinal stromal tumor (GIST) and pancreatic neuroendocrine tumor (PNET).
Another Plea to End the Insanity Wednesday, June 29, 2011 @ 7:41AMMexico is rapidly withering. Its very life is being siphoned off by a hopeless war on illegal drugs.
Threshold Pharmaceuticals Initiates Clinical Trial Evaluating TH-302 in Combination with Sunitinib Wednesday, June 29, 2011 @ 5:45AMREDWOOD CITY, Calif.--(BUSINESS WIRE)--Threshold Pharmaceuticals, Inc. (Nasdaq: THLD), today announced the initiation of a Phase 1/2 dose escalation clinical trial of TH-302 in combination with sunitinib in patients with advanced renal cell carcinoma (RCC), gastrointestinal stromal tumor (GIST) and pancreatic neuroendocrine tumor (PNET). TH-302 is a proprietary tumor selective Hypoxia-Activated ...
Penn Medicine News: Cancer Genetics Expert Chi Van Dang to Lead Penn Medicine's Abramson Cancer Center Tuesday, June 28, 2011 @ 8:55AMPHILADELPHIA — Chi Van Dang, MD, PhD, a renowned cancer biologist and hematologist-oncologist, has been appointed director of the Abramson Cancer Center of the University of Pennsylvania , effective September 1, 2011. Dr. Dang is currently a professor at The Johns Hopkins University School of Medicine in the departments of Medicine, Cell Biology, Oncology, Pathology, and Molecular Biology ...
Cancer Genetics Expert Chi Van Dang to Lead Penn Medicine's Abramson Cancer Center Monday, June 27, 2011 @ 1:35PMChi Van Dang, MD, PhD, a renowned cancer biologist and hematologist-oncologist, has been appointed director of the Abramson Cancer Center of the University of Pennsylvania, effective September 1, 2011.